JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Harrison, Claire; Kiladjian, Jean‐Jacques; Kathrin Al‐Ali, Haifa; Gisslinger, Heinz; J. Waltzman, Roger; Stalbovskaya, Viktoriya; McQuitty, Mari; Hunter, Deborah; Levy, Richard; Knoops, Laurent; Cervantes, Francisco; M. Vannucchi, Alessandro; Barbui, Tiziano; Barosi, Giovanni

doi:10.1056/nejmoa1110556

Public

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Published in New England Journal of Medicine • Feb 29, 2012

Authors:

Claire Harrison

Jean‐Jacques Kiladjian

Haifa Kathrin Al‐Ali

Abstract

BACKGROUND: Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis. METHODS: We assigned 219 patients with intermedi...

Subject

Ruxolitinib

Myelofibrosis

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!